Appendix 4D & Interim Financial Half Year Report FY2021
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Zelira Therapeutics Feasibility Study Update
- Company Update - Letter to Shareholders
- Prospectus - Placement
- Ordesa Feasibility Study Update
- Placement Offer to raise $2.76m
Later from Arovella Therapeutics
- Anagrelide Project Update
- Investor Presentation March 2021
- SUDA Licenses a Novel iNKT Cell Therapy Platform
- Investor Presentation incorporating iNKT Cell Platform
- SUDA Placement Raises $3.65m
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics